Monographie - Verapamil hydrochloride

Viimane versioon :
28/04/2024

Verapamil hydrochloride

Keemiline struktuur

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Calaptin	India
Calovera	India
Cordilox	Suurbritannia
Dilacoran	Mehhiko
Filacard	Saksamaa
Flamon	Sveits
Geangin	Taani
Isocor	Rumeenia
Isoptin	Ameerika ühendriigid, Austraalia, Austria, Egiptus, Holland, Itaalia, Kreeka, Poola, Portugal, Rootsi, Saksamaa, Saudi Araabia, Sveits, Uus-Meremaa
Isoptina	Tšiili
Isoptine	Belgia, Luksemburg, Prantsusmaa
Izoptomil	Egiptus
Lekoptin	Iraan
Manidon	Hispaania
Palyuan	Mehhiko
Securon	Suurbritannia
Serriten	Mehhiko
Unimylo	Mehhiko
Vasolan	Jaapan
Verahexal	Saksamaa
Veraloc	Taani
Veramex	Saksamaa
Verapabene	Austria
Verapam	Sveits
Verapamil	Ameerika ühendriigid, Kanada, Rootsi, Saksamaa, Ungari
Verapamilo	Argentiina, Ecuador, Kolumbia, Maroko, Tšiili
Verpamil	Malaisia, Soome

Viited : Verapamil hydrochloride

	Tüüp	Avaldamine
62	Ajaleht	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
191	Ajaleht	Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2079-2091.
242	Ajaleht	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
288	Ajaleht	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
300	Ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
364	Ajaleht	Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ. Compatibility of aminophylline and verapamil in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 97-100.
371	Ajaleht	Thompson DF, Stiles ML, Allen LV, Tu YH. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 142-145.
372	Ajaleht	Johnson CE, Lloyd CW, Aviles AI, Rybarz KL. Compatibility of premixed theophylline and verapamil intravenous admixtures. Am J Hosp Pharm 1988 ; 45: 609-612.
398	Ajaleht	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
660	Ajaleht	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
706	Ajaleht	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
921	Ajaleht	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1041	Ajaleht	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1045	Ajaleht	Das Gupta V, Stewart KR. Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections. Am J Hosp Pharm 1984 ; 41: 686-689.
1057	Ajaleht	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1098	Ajaleht	Cutie MR. Verapamil precipitation. Ann Intern Med 1983 ; 98: 672.
1099	Ajaleht	Tucker R, Gentile JF. Precipitation of verapamil in an intravenous line. Ann Intern Med 1984 ; 101: 880.
1100	Ajaleht	Bar-Or D, Kulig K, Marx JA, Rosen P. Precipitation of verapamil. Ann Intern Med 1982 ; 97: 619.
1232	Ajaleht	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1351	Ajaleht	Tucker R, Gentle JF. Precipitation of verapamil with nafcillin. Am J Hosp Pharm 1984 ; 41: 2588.
1508	Ajaleht	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1625	Ajaleht	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Ajaleht	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Ajaleht	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Ajaleht	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Ajaleht	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Ajaleht	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Ajaleht	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Ajaleht	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Ajaleht	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
2018	Ajaleht	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Ajaleht	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Ajaleht	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2328	Labor	Sugammadex (Bridion®) – Résumé des caractéristiques du produits Organon 2009
3766	Ajaleht	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Ajaleht	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3934	Labor	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
4130	Ajaleht	Koller AK, Krebs S, Dörje F. Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen. Pharmaceutics 2021 , 13, 21.
4603	Ajaleht	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Ajaleht	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales